Bank of New York Mellon
OLMA icon

Bank of New York Mellon’s Olema Pharmaceuticals OLMA Stock Holding History

Bank of New York Mellon’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
222,177
+28,694
+15% +$384K ﹤0.01% 2761
2026
Q1 		$2.88M Buy
193,483
+17,282
+10% +$385K ﹤0.01% 2624
2025
Q4 		$4.41M Buy
176,201
+7,004
+4% +$125K ﹤0.01% 2392
2025
Q3 		$1.66M Buy
169,197
+4,905
+3% +$29.5K ﹤0.01% 2919
2025
Q2 		$700K Buy
164,292
+32,298
+24% +$144K ﹤0.01% 3328
2025
Q1 		$496K Buy
131,994
+3,328
+3% +$16.7K ﹤0.01% 3442
2024
Q4 		$750K Sell
128,666
-3,516
-3% -$35.1K ﹤0.01% 3311
2024
Q3 		$1.58M Sell
132,182
-7,741
-6% -$99K ﹤0.01% 2873
2024
Q2 		$1.51M Buy
139,923
+58,622
+72% +$636K ﹤0.01% 2953
2024
Q1 		$920K Sell
81,301
-19,741
-20% -$255K ﹤0.01% 3200
2023
Q4 		$1.42M Buy
101,042
+9,235
+10% +$124K ﹤0.01% 2998
2023
Q3 		$1.13M Buy
91,807
+458
+0.5% +$4.67K ﹤0.01% 3083
2023
Q2 		$825K Buy
91,349
+79,149
+649% +$478K ﹤0.01% 3321
2023
Q1 		$42.3K Hold
12,200
– – ﹤0.01% 4218
2022
Q4 		$29.9K Hold
12,200
– – ﹤0.01% 4308
2022
Q3 		$34K Sell
12,200
-85
-0.7% -$360 ﹤0.01% 4382
2022
Q2 		$50K Sell
12,285
-75,080
-86% -$238K ﹤0.01% 4343
2022
Q1 		$372K Sell
87,365
-1,052
-1% -$5.8K ﹤0.01% 3889
2021
Q4 		$828K Buy
88,417
+6,781
+8% +$140K ﹤0.01% 3494
2021
Q3 		$2.25M Buy
81,636
+46,653
+133% +$1.26M ﹤0.01% 2921
2021
Q2 		$979K Buy
34,983
+2,953
+9% +$84K ﹤0.01% 3437
2021
Q1 		$1.06M Buy
+32,030
New +$1.37M ﹤0.01% 3296

Other funds holding OLMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's OLMA Position: Q2 2026 in Review

Bank of New York Mellon increased its Olema Pharmaceuticals (OLMA) stake by 15% in Q2 2026, buying an estimated $384K and bringing the position to 222,177 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2761.

Bank of New York Mellon first reported a position in OLMA in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.41M in Q4 2025. 49 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Bank of New York Mellon held 222,177 shares of Olema Pharmaceuticals worth $2.78M as of Q2 2026.
  • Bank of New York Mellon bought 28,694 Olema Pharmaceuticals shares in Q2 2026, an estimated $384K.
  • Olema Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2761 holding.
  • Bank of New York Mellon first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Bank of New York Mellon's Olema Pharmaceuticals position peaked at $4.41M in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.